Redeye reviews BioInvent’s fourth quarter. The company now has six active clinical programs with several readouts this year, which may be transformative for the company. In particular, three projects are set to be in phase IIa during the year, of which two (BI-1206 in NHL and BI-1808) will have phase IIa readouts.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BioInvent Q4 2023 - Now a mid-stage clinical company

© Modular Finance, source Nordic Press Releases